Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Stock Incentive Plan (Tables)

Note 5 - Stock Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		*Options Outstanding*
		*Number of Shares Subject to Options*				*Weighted-Average Exercise Price*
Balances at December 31, 2023			2,109,001			$	4.01
Granted⁽¹⁾			10,000				0.34
Forfeited⁽²⁾			—				—
Balances at March 31, 2024			2,119,001				4.00
Unvested options outstanding expected to vest⁽³⁾			543,578				3.30

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise Prices		Number of Shares Subject to Options Outstanding				Weighted-Average Remaining Contractual Term in Years				Number of Shares Subject to Options Fully Vested and Exercisable				Weighted-Average Remaining Contractual Term in Years
$0.001 - $5.00			1,381,895				6.73				887,939				5.73
$5.01 - $10.00			617,942				5.25				568,320				5.09
$10.01 - $15.00			113,039				5.84				113,039				5.84
$15.01 - $20.00			6,125				5.84				6,125				5.84
			2,119,001				6.25				1,575,423				5.51

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

						*Weighted- Average*
		*Restricted*				*Grant Date*
		*Stock Units*				*Fair Value*
		*(#)*				*per Unit ($)*
Unvested balance at December 31, 2023			418,091				3.40
Granted⁽¹⁾			—				—
Vested			(51,557	)			4.91
Unvested Balance at March 31, 2024			366,534				3.19

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

		*Three Months Ended March 31,*
		*2024*				*2023*

Stock options granted			10,000				508,902
Weighted-average grant date fair value per share		$	0.25			$	2.38
Fair value of shares vested		$	178,650			$	223,273